Lee, K., Lee, K., Kim, D., Yoon, J., Choi, Y. J., Lee, S., . . . Park, I. H. Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20‐17/KM23 trial. Wiley.
Chicago Style (17th ed.) CitationLee, Kyoungmin, et al. Phase II Study Evaluating the Safety and Efficacy of Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Tumors: KCSG AL20‐17/KM23 Trial. Wiley.
MLA (9th ed.) CitationLee, Kyoungmin, et al. Phase II Study Evaluating the Safety and Efficacy of Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Tumors: KCSG AL20‐17/KM23 Trial. Wiley.
Warning: These citations may not always be 100% accurate.